Detalhe da pesquisa
1.
A European, prospective, observational study of enzalutamide in patients with metastatic castration-resistant prostate cancer: PREMISE.
Int J Cancer
; 150(5): 837-846, 2022 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34648657
2.
Enzalutamide with androgen deprivation therapy in Japanese men with metastatic hormone-sensitive prostate cancer: A subgroup analysis of the phase III ARCHES study.
Int J Urol
; 28(7): 765-773, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33955599
3.
Efficacy and Safety of Enzalutamide vs Bicalutamide in Younger and Older Patients with Metastatic Castration Resistant Prostate Cancer in the TERRAIN Trial.
J Urol
; 199(1): 147-154, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28827103
4.
Long-Term Antitumor Activity and Safety of Enzalutamide Monotherapy in Hormone Naïve Prostate Cancer: 3-Year Open Label Followup Results.
J Urol
; 199(2): 459-464, 2018 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-28867562
5.
Safety, tolerability and anti-tumour activity of the androgen biosynthesis inhibitor ASP9521 in patients with metastatic castration-resistant prostate cancer: multi-centre phase I/II study.
Invest New Drugs
; 32(5): 995-1004, 2014 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-24771350
6.
ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer.
J Clin Oncol
; 37(32): 2974-2986, 2019 11 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31329516
7.
Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for ≥24 weeks in Europe.
Eur Urol
; 74(1): 37-45, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-28844372
8.
Implications of circadian clocks for the rhythmic delivery of cancer therapeutics.
Adv Drug Deliv Rev
; 59(9-10): 1015-35, 2007 Aug 31.
Artigo
em Inglês
| MEDLINE | ID: mdl-17692427
9.
Impact of Enzalutamide Compared with Bicalutamide on Quality of Life in Men with Metastatic Castration-resistant Prostate Cancer: Additional Analyses from the TERRAIN Randomised Clinical Trial.
Eur Urol
; 71(4): 534-542, 2017 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-27497762
10.
Using the continual reassessment method: lessons learned from an EORTC phase I dose finding study.
Eur J Cancer
; 42(10): 1362-8, 2006 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-16740385
11.
Elevated serum cytokines correlated with altered behavior, serum cortisol rhythm, and dampened 24-hour rest-activity patterns in patients with metastatic colorectal cancer.
Clin Cancer Res
; 11(5): 1757-64, 2005 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-15755997
12.
Long-term Efficacy and Safety of Enzalutamide Monotherapy in Hormone-naïve Prostate Cancer: 1- and 2-Year Open-label Follow-up Results.
Eur Urol
; 68(5): 787-94, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-25687533
13.
Cost effectiveness of paclitaxel/cisplatin compared with cyclophosphamide/cisplatin in the treatment of advanced ovarian cancer in Belgium.
Pharmacoeconomics
; 20(7): 485-97, 2002.
Artigo
em Inglês
| MEDLINE | ID: mdl-12093304
14.
A randomized multicenter study of optimal circadian time of vinorelbine combined with chronomodulated 5-fluorouracil in pretreated metastatic breast cancer patients: EORTC trial 05971.
Chronobiol Int
; 25(5): 680-96, 2008 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-18780198
15.
Comparison of CA-125 and standard definitions of progression of ovarian cancer in the intergroup trial of cisplatin and paclitaxel versus cisplatin and cyclophosphamide.
J Clin Oncol
; 24(1): 45-51, 2006 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-16382112
16.
Phase III trial comparing 4-day chronomodulated therapy versus 2-day conventional delivery of fluorouracil, leucovorin, and oxaliplatin as first-line chemotherapy of metastatic colorectal cancer: the European Organisation for Research and Treatment of Cancer Chronotherapy Group.
J Clin Oncol
; 24(22): 3562-9, 2006 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-16877722